TMThomas D. Martin

Thomas D. Martin

*This is an algorithmically generated author record based on publicly available information.

Thomas D. Martin has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Li Wu

    Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa

    7 shared publications
  • Vineet N. KewalRamani

    Laboratory of Experimental and Computational Biology,1 HIV-Drug Resistance Program,2 Laboratory of Molecular Immunoregulation, Center for Cancer Research, NCI-Frederick, National Institutes of Health, Frederick, Maryland 217023

    5 shared publications
  • Alok Mulky

    HIV Drug Resistance Program, National Cancer Institute

    3 shared publications
  • Arman A. Bashirova

    Science Application International Corporation at Frederick, Laboratory of Genomic Diversity, National Cancer Institute at Frederick, Maryland 21702, USA

    3 shared publications
  • Derya Unutmaz

    Department of Microbiology and Pathology, NYU School of Medicine, New York, NY, 10016

    3 shared publications
  • Mary Carrington

    The ‖Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

    3 shared publications

Latest Publications

  • Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody–Drug Conjugates Using Click Cycloaddition Chemistry

    by Michael P. VanBrunt, Kurt Shanebeck, Zachary Caldwell, Jeffrey Johnson, Pamela Thompson, Thomas Martin, Huifang Dong, Gary Li, Hengyu Xu, Francois D’hOoge, et al.

    Antibody–drug conjugates (ADC) have emerged as potent antitumor drugs that provide increased efficacy, specificity, and tolerability over chemotherapy for the treatment of cancer. ADCs generated by targeting cysteines and lysines on the antibody have shown efficacy, but these products are heterogeneous, and instability may limit their dosing. Here, a novel technology is described that enables site-specific conjugation of toxins to antibodies using chemistry to produce homogeneous, potent, and highly stable conjugates. We have developed a cell-based mammalian expression system capable of site-specific integration of a non-natural amino acid containing an azide moiety. The azide group enables click cycloaddition chemistry that generates a stable heterocyclic triazole linkage. Antibodies to Her2/neu were expressed to contain N6-((2-azidoethoxy)carbonyl)-l-lysine at four different positions. Each site allowed over 95% conjugation efficacy with the toxins auristatin F or a pyrrolobenzodiazepine (PBD) dimer to generate ADCs with a drug to antibody ratio of >1.9. The ADCs were potent and specific in in vitro cytotoxicity assays. An anti Her2/neu conjugate demonstrated stability in vivo and a PBD containing ADC showed potent efficacy in a mouse tumor xenograph model. This technology was extended to generate fully functional ADCs with four toxins per antibody. The high stability of the azide–alkyne linkage, combined with the site-specific nature of the expression system, provides a means for the generation of ADCs with optimized pharmacokinetic, biological, and biophysical properties.


  • HIV-1 Capsid-Targeting Domain of Cleavage and Polyadenylation Specificity Factor 6

    by KyeongEun Lee, Alok Mulky, Wendy Yuen, Thomas D. Martin, Nicholas R. Meyerson, Laura Choi, Hyun Yu, Sara L. Sawyer, Vineet N. KewalRamani

    The antiviral factor CPSF6-358 restricts human immunodeficiency virus type 1 (HIV-1) infection through an interaction with capsid (CA), preventing virus nuclear entry and integration. HIV-1 acquires resistance to CPSF6-358 through an N74D mutation of CA that impairs binding of the antiviral factor. Here we examined the determinants within CPSF6-358 that are necessary for CA-specific interaction. Residues 314 to 322 include amino acids that are essential for CPSF6-358 restriction of HIV-1. Fusion of CPSF6 residues 301 to 358 to rhesus TRIM5α is also sufficient to restrict wild-type but not N74D HIV-1. Restriction is lost if CPSF6 residues in the amino acid 314 to 322 interaction motif are mutated. Examination of the CA targeting motif in CPSF6-358 did not reveal evidence of positive selection. Given the sensitivity of different primate lentiviruses to CPSF6-358 and apparent conservation of this interaction, our data suggest that CPSF6-358-mediated targeting of HIV-1 could provide a broadly effective antiviral strategy.


  • Top Cited Papers

    Flexible Use of Nuclear Import Pathways by HIV-1

    by KyeongEun Lee, Zandrea Ambrose, Thomas D. Martin, Ilker Oztop, Alok Mulky, John G. Julias, Nick Vandegraaff, Joerg G. Baumann, Rui Wang, Wendy Yuen, et al.


  • Open Access

    HIV-1 Transmission by Dendritic Cell-specific ICAM-3-grabbing Nonintegrin (DC-SIGN) Is Regulated by Determinants in the Carbohydrate Recognition Domain That Are Absent in Liver/Lymph Node-SIGN (L-SIGN)

    by Nancy P. Y. Chung, Sabine K. J. Breun, Arman Bashirova, Joerg G. Baumann, Thomas D. Martin, Jaideep M. Karamchandani, Jason W. Rausch, Stuart F. J. Le Grice, Li Wu, Mary Carrington, et al.


  • 117 CA-Dependent HIV-1 Nuclear Import Relies on Transportin-SR2

    by Kyeongeun Lee, Thomas D Martin, Zandrea Ambrose, Alok Mulky, Vineet N KewalRamani

  • Open Access

    Elevated Expression of GM3 in Receptor-Bearing Targets Confers Resistance to Human Immunodeficiency Virus Type 1 Fusion

    by Satinder S. Rawat, Stephen A. Gallo, Julie Eaton, Thomas D. Martin, Sherimay Ablan, Vineet N. KewalRamani, Ji Ming Wang, Robert Blumenthal, Anu Puri

    GM3, a major ganglioside of T lymphocytes, promotes human immunodeficiency virus type 1 (HIV-1) entry via interactions with HIV-1 receptors and the viral envelope glycoprotein (Env). Increased GM3 levels in T lymphocytes and the appearance of anti-GM3 antibodies in AIDS patients have been reported earlier. In this study, we investigated the effect of GM3 regulation on HIV-1 entry by utilizing a mouse cell line (B16F10), which expresses exceptionally high levels of GM3. Strikingly, B16 cells bearing CD4, CXCR4, and/or CCR5 were highly resistant to CD4-dependent HIV-1 Env-mediated membrane fusion. In contrast, these targets supported membrane fusion mediated by CD4-requiring HIV-2, SIV, and CD4-independent HIV-1 Envs. Coreceptor function was not impaired by GM3 overexpression as indicated by Ca2+ fluxes mediated by the CXCR4 ligand SDF-1α and the CCR5 ligand MIP-1β. Reduction in GM3 levels of B16 target cells resulted in a significant recovery of CD4-dependent HIV-1 Env-mediated fusion. We propose that GM3 in the plasma membrane blocks HIV-1 Env-mediated fusion by interfering with the lateral association of HIV-1 receptors. Our findings offer a novel mechanism of interplay between membrane lipids and receptors by which host cells may escape viral infections.


  • Open Access

    Trans-dominant cellular inhibition of DC-SIGN-mediated HIV-1 transmission

    by Li Wu, Thomas D Martin, Yoon-Chi Han, Sabine Kj Breun, Vineet N KewalRamani

    Dendritic cell (DC) transmission of human immunodeficiency virus (HIV) to CD4+ T cells occurs across a point of cell-cell contact referred to as the infectious synapse. The relationship between the infectious synapse and the classically defined immunological synapse is not currently understood. We have recently demonstrated that human B cells expressing exogenous DC-SIGN, DC-specific intercellular adhesion molecule-3 (ICAM-3)-grabbing nonintegrin, efficiently transmit captured HIV type 1 (HIV-1) to CD4+ T cells. K562, another human cell line of hematopoietic origin that has been extensively used in functional analyses of DC-SIGN and related molecules, lacks the principal molecules involved in the formation of immunological synaptic junctions, namely major histocompatibility complex (MHC) class II molecules and leukocyte function-associated antigen-1 (LFA-1). We thus examined whether K562 erythroleukemic cells could recapitulate efficient DC-SIGN-mediated HIV-1 transmission (DMHT). Here we demonstrate that DMHT requires cell-cell contact. Despite similar expression of functional DC-SIGN, K562/DC-SIGN cells were inefficient in the transmission of HIV-1 to CD4+ T cells when compared with Raji/DC-SIGN cells. Expression of MHC class II molecules or LFA-1 on K562/DC-SIGN cells was insufficient to rescue HIV-1 transmission efficiency. Strikingly, we observed that co-culture of K562 cells with Raji/DC-SIGN cells impaired DMHT to CD4+ T cells. The K562 cell inhibition of transmission was not directly exerted on the CD4+ T cell targets and required contact between K562 and Raji/DC-SIGN cells. DMHT is cell type dependent and requires cell-cell contact. We also find that the cellular milieu can negatively regulate DC-SIGN transmission of HIV-1 in trans.


  • Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission

    by Li Wu, Thomas D. Martin, Mary Carrington, Vineet N. KewalRamani


  • Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion

    by Satinder S. Rawat, Julie Eaton, Stephen A. Gallo, Thomas D. Martin, Sherimay Ablan, Shashikala Ratnayake, Mathias Viard, Vineet N. KewalRamani, Ji Ming Wang, Robert Blumenthal, et al.


  • Novel Member of the CD209 ( DC-SIGN ) Gene Family in Primates

    by Arman A. Bashirova, Li Wu, Jie Cheng, Thomas D. Martin, Maureen P. Martin, Raoul E. Benveniste, Jeffrey D. Lifson, Vineet N. KewalRamani, Austin Hughes, Mary Carrington

    Two CD209 family genes identified in humans, CD209 ( DC-SIGN ) and CD209L ( DC-SIGNR / L-SIGN ), encode C-type lectins that serve as adhesion receptors for ICAM-2 and ICAM-3 and participate in the transmission of human and simian immunodeficiency viruses (HIV and SIV, respectively) to target cells in vitro. Here we characterize the CD209 gene family in nonhuman primates and show that recent evolutionary alterations have occurred in this family across primate species. All of the primate species tested, specifically, Old World monkeys (OWM) and apes, have orthologues of human CD209 . In contrast, CD209L is missing in OWM but present in apes. A third family member, that we have named CD209L2 , was cloned from rhesus monkey cDNA and subsequently identified in OWM and apes but not in humans. Rhesus CD209L2 mRNA was prominently expressed in the liver and axillary lymph nodes, although preliminary data suggest that levels of expression may vary among individuals. Despite a high level of sequence similarity to both human and rhesus CD209, rhesus CD209L2 was substantially less effective at binding ICAM-3 and poorly transmitted HIV type 1 and SIV to target cells relative to CD209. Our data suggest that the CD209 gene family has undergone recent evolutionary processes involving duplications and deletions, the latter of which may be tolerated because of potentially redundant functional activities of the molecules encoded by these genes.